Wilson Therapeutics, a Stockholm, Sweden-based biopharmaceutical company, received $40m in Series B funding.
The round was co-led by Abingworth LLP and MVM Life Science Partners, with participation from founding investor HealthCap. In conjunction with the funding, Bali Muralidhar, M.D., Ph.D., Partner at MVM, and Genghis Lloyd-Harris, M.D., Ph.D., Partner at Abingworth, will both join the Wilson Therapeutics Board of Directors.
The company intends to use the funds to advance clinical development of a new treatment for Wilson’s disease.
Led by Jonas Hansson, Chief Executive Officer, Wilson Therapeutics is advancing WTX101 (bis-choline tetrathiomolybdate), a novel de-coppering agent being developed as a new treatment for Wilson’s disease, a rare genetic disorder that prevents the body from regulating copper and can lead to serious liver and brain damage.